Decongestant Patents (Class 514/853)
-
Patent number: 8992916Abstract: The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.Type: GrantFiled: October 2, 2013Date of Patent: March 31, 2015Assignee: Novartis AGInventors: Emma Michelle Campbell, Sofia Parveen, Joe Buechler, Gunars Valkirs
-
Patent number: 8940319Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.Type: GrantFiled: June 1, 2012Date of Patent: January 27, 2015Assignee: Accentia Biopharmceuticals, Inc.Inventors: Francis E. O'Donnell, Angelos M. Stergiou
-
Patent number: 8263124Abstract: The present invention relates to pharmaceutical compositions of antihistamine-decongestant combination. Specifically the invention relates to bilayered tablet formulation comprising antihistaminic decongestant combination. More specifically present invention relates to the novel polymorph of fexofenadine or pharmaceutically accepted salts thereof, with at least one decongestant in the form of bilayered tablet. The preferred polymorphs are polymorph A and polymorph X of fexofenadine hydrochloride.Type: GrantFiled: April 4, 2002Date of Patent: September 11, 2012Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.Inventors: Kamalakar Talasila, Debashis Dash, Srinivas Irukula, Dhanorkar Vipin Tatyasaheb, Mailatur Sivaraman Mohan
-
Patent number: 8257746Abstract: Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions.Type: GrantFiled: July 28, 2011Date of Patent: September 4, 2012Assignee: Pernix Therapeutics, LLCInventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
-
Patent number: 8211460Abstract: The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.Type: GrantFiled: August 3, 2009Date of Patent: July 3, 2012Assignee: Accentia Biopharmaceuticals, Inc.Inventors: Francis E. O'Donnell, Jr., Angelos M. Stergiou
-
Patent number: 8012506Abstract: Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions.Type: GrantFiled: August 9, 2006Date of Patent: September 6, 2011Assignee: Pernix Therapeutics, LLCInventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
-
Patent number: 7348360Abstract: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.Type: GrantFiled: January 3, 2005Date of Patent: March 25, 2008Assignee: Zicam, LLCInventors: Charles Hensley, Robert Steven Davidson
-
Patent number: 7128897Abstract: Pharmaceutical compositions are described that contain one agent for treatment of sinusitis and a surfactant. The compositions are prepared to have a surface tension that renders the composition effective for treatment of sinusitis.Type: GrantFiled: August 28, 2002Date of Patent: October 31, 2006Assignee: Naryx Pharma, Inc.Inventors: Robert S. Osbakken, Mary Anne Hale, Frederick T. Leivo, James D. Munk
-
Patent number: 7094429Abstract: An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then added to a liquid or semi-solid medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liquid or semi-solid medium to generate a therapeutic dosage form.Type: GrantFiled: August 19, 2004Date of Patent: August 22, 2006Assignee: Kiel Laboratories, Inc.Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
-
Patent number: 7087249Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.Type: GrantFiled: April 23, 2002Date of Patent: August 8, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventors: Robert Edward Burrell, Antony George Naylor, Peter Howard Moxham
-
Patent number: 7060730Abstract: The present invention provides a method which provides for a faster absorption of pharmaceutically acceptable amines. The method provides a pharmaceutically acceptable amine in combination with a non-steroidal anti-inflammatory drug in a liquid form. A preferred embodiment employs pseudoephedrine and ibuprofen.Type: GrantFiled: June 26, 2003Date of Patent: June 13, 2006Inventors: Cathy Klech Gelotte, Joanna F. Hills, Charles E. Pendley, II, Manoj N. Shah
-
Patent number: 7029705Abstract: A method is disclosed of practicing nasal hygiene comprising the steps of applying to a person's nostril a non-irritating hygienic composition consisting essentially of a product of compounding under homogenizing conditions water, 0.01% to 5% by weight, as chlorine dioxide, of a source of chlorine dioxide; 0.01% to 3% by weight of at least one olfactory stimulant, 0 to 5% by weight of at least one fixative compound less volatile than the olfactory stimulant 0.1 to 2.5% by weight of at least one inorganic salt selected from the group consisting of alkali metal chloride, alkali metal bicarbonate, and alkali metal chlorate; and 0.0002 to 0.006% (as aluminum) by weight of at least one water soluble aluminum compound, provided that the total concentration of inorganic salt is in the range from 0.6% by weight to 2.5% by weight, holding the composition within the nostril for a hygienic holding period, and discharging the composition from the treated nostril.Type: GrantFiled: July 30, 2003Date of Patent: April 18, 2006Inventor: Allan H. Fuhr
-
Patent number: 6989157Abstract: Dry powders of metal-containing compounds are disclosed. Methods of preparing and using the dry powders, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.Type: GrantFiled: October 22, 2002Date of Patent: January 24, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventors: Scott H. Gillis, Paul Schechter, Robert E. Burrell
-
Patent number: 6869618Abstract: An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then added to a liquid or semi-solid medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liquid or semi-solid medium to generate a therapeutic dosage form.Type: GrantFiled: April 9, 2002Date of Patent: March 22, 2005Assignee: Kiel Laboratories, Inc.Inventors: Jeffrey S. Kiel, H. Greg Thomas, Narasimhan Mani
-
Patent number: 6866871Abstract: Dry powders of metal-containing compounds are disclosed. Methods of preparing and using the dry powders, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.Type: GrantFiled: October 22, 2002Date of Patent: March 15, 2005Assignee: Nucryst Pharmaceuticals Corp.Inventors: Scott H. Gillis, Paul Schechter, Robert E. Burrell
-
Patent number: 6841146Abstract: An aqueous-based sprayable composition comprises a therapeutic or palliative agent, water and a mixture of microcrystalline cellulose and alkali metal carboxyalkylcellulose. In one embodiment, the composition is a non-Newtonian nasal spray exhibiting a very rapid viscosity recovery upon removal of shear forces.Type: GrantFiled: March 19, 2003Date of Patent: January 11, 2005Assignee: Schering-Plough Healthcare Products Inc.Inventors: Joseph A. Haslwanter, William J. McLaughlin, David M. Oakley, Kurt G. Van Scoik
-
Patent number: 6790849Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.Type: GrantFiled: March 26, 2002Date of Patent: September 14, 2004Assignee: Sepracor Inc.Inventor: Paul D. Rubin
-
Patent number: 6780398Abstract: An aqueous nasal formulation comprising beclomethasone dipropionate anhydrate for use in the treatment of respiratory disorders.Type: GrantFiled: May 16, 2002Date of Patent: August 24, 2004Assignee: Glaxo Smithkline Kabushiki KaishaInventors: Rika Akutsu, Kenji Hosoya, Koho Kawamura, Yasuhiro Mishima, Tomohisa Onozaki, Nobuya Sugibayashi
-
Patent number: 6767901Abstract: The present invention provides a pharmaceutical composition for application to the mucosa to be used in drug therapy comprising a water-insoluble and/or water-low soluble substance, ciclesonide, and an aqueous medium, and having an osmotic pressure of less than 290 mOsm. This composition is superior over conventional pharmaceutical compositions for application to the mucosa, due to efficient and high ciclesonide retentivity and permeability to the submucosa or the blood at the mucosa.Type: GrantFiled: July 15, 2002Date of Patent: July 27, 2004Assignee: Altana Pharma AGInventors: Atsuhiro Nagano, Yoshihisa Nishibe, Kazuya Takanashi
-
Patent number: 6703376Abstract: A method of promoting drainage of mucous secretions in the congested airways of a bedridden/immobilized patient or an intubated/mechanically-ventilated patient is disclosed. The method comprises administering to the airways of the patient a uridine phosphate such as uridine 5′-triphsophate(UTP) or P1,P4-di(uridine-5′) tetraphosphate, an analog of UTP, or any other analog, in an amount effective to promote drainage of fluid in the congested airways, including sinuses, to create the ciliary beat frequency of cilia on the surface lumina epithelia cells, to increase the secretions of mucous by goblet cells and to promote the clearance of retained secretions by hydrating mucous secretions, by stimulating ciliary beat frequency in the airways and by stimulating surfactant production. Pharmaceutical formulations and methods of making the same are also disclosed.Type: GrantFiled: December 22, 1998Date of Patent: March 9, 2004Assignee: Inspire Pharmaceuticals, Inc.Inventors: Karla M. Jacobus, H. Jeff Leighton
-
Patent number: 6645532Abstract: Generally, the method for preventing or relieving discomfort in the ears arising from congestion and/or obstruction of in the eustachian tubes comprising or changes in middle ear pressure relative to atmospheric pressure arising from environmental conditions in an individual need of prevention or relief from discomfort in the ears comprises the steps of: 1) administering a solution of 1.5%-3.5% (preferably 2-3%) sodium chloride solution having a pH of about 6 to 7.8 (preferably 6.5-7.5) in an aqueous solution as a spray or mist into the nose, 2) minimizing discharge of the solution from the nose for at least 5 seconds, then 3) evacuating the nose under pressure.Type: GrantFiled: January 19, 2000Date of Patent: November 11, 2003Inventor: Matthew Lutin
-
Patent number: 6641799Abstract: A therapeutic composition for use as a nasal spray the aids in decongesting of the nasal passages by osmotic effect, thinning of mucus and stimulation of ciliary function. Preferred embodiments of the composition contain a sugar solution, a sodium bicarbonate solution, saline, glycerin, water, and a preservative.Type: GrantFiled: April 3, 2002Date of Patent: November 4, 2003Assignee: Nos Spray, Inc.Inventor: Trevor Ian Goldberg
-
Patent number: 6599914Abstract: Methods of inhibiting the generation of pro-inflammatory cytokines such as IL-4 and IL-13 in a human patient in need of such inhibiting are disclosed.Type: GrantFiled: April 24, 2001Date of Patent: July 29, 2003Assignee: Schering CorporationInventors: Robert P. Schleimer, John Schroeder, William Kreutner
-
Patent number: 6565832Abstract: An aqueous-based sprayable composition comprises a therapeutic or palliative agent, water and a mixture of microcrystalline cellulose and alkali metal carboxyalkylcellulose. In one embodiment, the composition is a non-Newtonian nasal spray exhibiting a very rapid viscosity recovery upon removal of shear forces.Type: GrantFiled: January 31, 2000Date of Patent: May 20, 2003Assignee: Schering-Plough HealthCare Products, Inc.Inventors: Joseph A. Haslwanter, William J. McLaughlin, David M. Oakley, Kurt G. Van Scoik
-
Patent number: 6509043Abstract: A composition comprising (a) soy protein, (b) a phytoestrogen compound, and (c) dietary fibers. The soy protein (a) is present in an amount of at least 45 weight percent of the total protein content of the composition, said total protein content providing at least 15% of the total energy content of the composition. The phytoestrogen compound (b) is preferably a naturally occurring isoflavone and is present in an amount of more than 0.10 weight percent of the soy protein, and the dietary fibers (c) are preferably soybean fibers and are present in an amount of more than 4 weight percent of the total weight of the nutritional composition on a dry basis. The composition is useful for treating pulmonary diseases.Type: GrantFiled: August 15, 2001Date of Patent: January 21, 2003Assignee: Nutri Pharma ASAInventor: Lars Henrik Høie
-
Patent number: 6451352Abstract: The invention concerns the use of iso-osmotic saline solutions in particular obtained from sea water, to obtain a medicine designed for a treatment preventing and limiting the release of chemical mediators responsible for causing inflammatory phenomena in the human respiratory tracts.Type: GrantFiled: May 24, 2001Date of Patent: September 17, 2002Assignee: Laboratoires Goemar S.A.Inventors: Jean-Claude Yvin, Olivier Tabary, Jacky Jacquot, Edith Puchelle
-
Patent number: 6410046Abstract: A device, methods and pharmaceutical compositions are disclosed for transnasal or transocular drug delivery to the central nervous system using a combination of electrotransport or phonophoresis with chemical permeation enhancers.Type: GrantFiled: November 20, 1998Date of Patent: June 25, 2002Assignee: Intrabrain International NVInventor: Eduard N. Lerner
-
Patent number: 6384038Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.Type: GrantFiled: April 14, 1998Date of Patent: May 7, 2002Assignee: Sepracor Inc.Inventor: Paul D. Rubin
-
Publication number: 20010053787Abstract: Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole.Type: ApplicationFiled: April 16, 2001Publication date: December 20, 2001Applicant: Sepracor Inc.Inventors: Raymond L. Woosley, A. K. Gunnar Aberg
-
Patent number: 6316483Abstract: Aqueous nasal spray compositions comprising a medicament and an aqueous carrier comprising water soluble polymers selected from the group consisting of polyvinylpyrrolidone and mixtures thereof.Type: GrantFiled: November 5, 1999Date of Patent: November 13, 2001Assignee: Schering CorporationInventors: Joseph A. Haslwanter, William F. Rencher
-
Patent number: 6287597Abstract: Tannate compositions consisting essentially of pyrilamine tannate and phenylephrine tannate which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis and upper respiratory tract conditions are disclosed.Type: GrantFiled: March 12, 1999Date of Patent: September 11, 2001Assignee: Carter-Wallace, Inc.Inventor: Steven A. Gordziel
-
Patent number: 6211246Abstract: The present invention provides a method which provides for a faster absorption of pharmaceutically acceptable amines. The method provides a pharmaceutically acceptable amine in combination with a non-steroidal anti-inflammatory drug in a liquid form. A preferred embodiment employs pseudoephedrine and ibuprofen.Type: GrantFiled: June 10, 1999Date of Patent: April 3, 2001Assignee: McNeil-PPC, Inc.Inventors: Cathy Klech Gelotte, Joanna F. Hills, Charles E. Pendley, II, Manoj N. Shah
-
Patent number: 6180663Abstract: A therapeutic nasal inhalant for using bioflavanoids as a topical antioxidant. The therapeutic nasal inhalant includes a method for making a therapeutic nasal inhalant composition for treating nasal mucosa. The method comprises the steps of mixing together two cups of water, one teaspoon of baking soda, one teaspoon of sodium chloride, and four milligrams of vitamin C to form a mixture. Mixing a bioflavanoid with the mixture. Allowing the mixture to stand. Filtering the mixture. Allowing the mixture to stand for a second time. Filtering the mixture.Type: GrantFiled: December 3, 1999Date of Patent: January 30, 2001Inventor: Stanley Lang
-
Patent number: 6113945Abstract: The medicament of the present invention and its process of manufacturing employs a caplet or tablet core with a clear or single color uniform covering which can be applied either through an enrobing process, by spraying or by a single dip-coating step. The core itself can have a first color or be colorless, and its clear or single color covering has the outer surface of one end or one side colored by a suitable dye to provide a two-color appearance. The dye can be applied by dipping or spray painting with a suitable jet-spraying apparatus. In a preferred embodiment, the covering is of a clear gelatinous material.Type: GrantFiled: February 26, 1996Date of Patent: September 5, 2000Assignee: L. Perrigo CompanyInventors: Richard L. Jacobs, Shirish A. Shah
-
Pharmaceutical suppository composites for fever and influenza and method of producing the composites
Patent number: 6063383Abstract: Pharmaceutical suppository composites for fever and influenza and method of producing them, therefore, are disclosed herein. More particularly, the composites combine all the advantages of traditional Chinese medicine, western medicine, and physical temperature reduction to relieve symptoms of influenza. Poisonous side effects can be avoided by using the disclosed suppositories. The pharmaceutical suppository composites comprise 2,750 g to 3,250 g radix bupleuri scorzonerifolium wild, 1,750 g to 2,250 g flos lonicerae japonicae, 1,950 g to 2,450 g fructus forsythiae, 1,650 g to 2,150 g fructus arctii, 2,550 g to 3,050 g herba schizonepetae, 50 g to 550 g calculus bovis and 870 g to 1,370 g of excipients.Type: GrantFiled: January 28, 1999Date of Patent: May 16, 2000Inventors: Wu-Ching Hsu, Su-Hsien Keng -
Patent number: 6051585Abstract: An oral once-per-day single dosage unit for treating the symptoms of rhinitis expertly formulated with a nasal decongestant and antihistamine. Preferably, the antihistamine is non-sedating.Type: GrantFiled: December 7, 1998Date of Patent: April 18, 2000Inventors: Robert E. Weinstein, Alan M. Weinstein
-
Patent number: 6039974Abstract: The present invention provides a pharmaceutical composition in the form of a bilayer tablet comprising,(a) a first discrete zone made with Formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, in an amount of about 18% to about 39% by weight of Formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of;(I) carnauba wax in an amount of about 59% to about 81% by weight of Formulation (A); and(ii) a suitable antiadherent in an amount of about 0.25% to about 2.Type: GrantFiled: July 31, 1998Date of Patent: March 21, 2000Assignee: Hoechst Marion Roussel, Inc.Inventors: David D. MacLaren, John R. Lefler, Sharon K. Minish
-
Patent number: 5948414Abstract: This invention relates to an improved herbal-based decongestant and antihistamine nasal spray which includes known constituents in specific ratios and further includes a saponin. The invention further relates to a method for treating nasal congestion which results in enhanced decongestant action and surprising curative effects.Type: GrantFiled: March 24, 1998Date of Patent: September 7, 1999Assignee: Nouveau Technologies, Inc.Inventor: Jack G. Wiersma
-
Patent number: 5922760Abstract: An agent for the prevention or alleviation of allergy symptoms contains as an effective component a dioxabycyclo?3.3.0!octane derivative represented by the following general formula (I): ##STR1## where R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 each independently represent a hydrogen atom or alkyl group of 1-3 carbon atoms, or R.sup.1 and R.sup.2 and/or R.sup.4 and R.sup.5 together represent a methylene or ethylene group, and n, m and l represent 0 or 1.An agent for the prevention or alleviation of allergy symptoms also contains as an effective component an antioxidant in addition to the dioxabicyclo?3.3.0!octane derivative.Type: GrantFiled: June 19, 1997Date of Patent: July 13, 1999Assignee: Suntory LimitedInventors: Kengo Akimoto, Michihiro Sugano, Koji Yamada, Michiko Nonaka, Jiong-Yan Gu
-
Patent number: 5897858Abstract: Aqueous nasal spray compositions containing:0.001-2% by weight/volume of a medicament selected from the group consisting of chlorpheniramine maleate, oxymetazoline hydrochloride and mixtures thereof;0.50 to 15.00% by weight/volume of a water soluble polymer selected from the group consisting of polyvinylpyrrolidone having an average molecular weight of about 10,000 to 360,000 and mixtures thereof;2.5 to 10.00% by weight/volume of polyethylene glycol;1.00 to 10.00% by weight/volume of a moisturizing agent other than polyethylene glycol;0.01 to 0.05% by weight/volume of disodium edetate;0.001 to 0.3% by weight/volume of an antimicrobial preservative;0.20 to 5.00% by weight/volume of an aromatic alcohol;a sufficient amount of a pharmaceutically acceptable buffer to maintain the pH of the composition within the range of about 4.0 to 8.0; andQS water.Type: GrantFiled: November 4, 1997Date of Patent: April 27, 1999Assignee: Schering-Plough Healthcare Products, Inc.Inventors: Joseph A. Haslwanter, William F. Rencher
-
Patent number: 5837286Abstract: This invention provides a taste masking composition composed of clove oil and either supportive flavor components or calcium carbonate. This taste masking composition has been found to be particularly useful to mask unpalatable medicinals in formulations which are intended to be chewed, dissolve in the mouth prior to ingestion or ingested in solution.Type: GrantFiled: January 15, 1997Date of Patent: November 17, 1998Inventors: Harish B. Pandya, Thomas P. Callahan
-
Patent number: 5830490Abstract: A method and device for organizing, storing, instructing, and coordinating the combined use of aerosol and oral medications for the treatment of disorders including respiratory tract disorders for the purpose of reducing medication error and increasing therapeutic compliance.Type: GrantFiled: April 4, 1997Date of Patent: November 3, 1998Inventors: Robert E. Weinstein, Alan M. Weinstein
-
Patent number: 5760085Abstract: The present invention relates to topical aromatic releasing compositions containing one or more volatile aromatic compounds selected from the group consisting of 3-1-menthoxy propane-1,2-diol, N-substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof. In further embodiments, these compositions are also useful for providing relief from nasal symptoms.Type: GrantFiled: September 12, 1996Date of Patent: June 2, 1998Assignee: The Procter & Gamble CompanyInventors: William Fletcher Beck, Sekhar Mitra
-
Patent number: 5725865Abstract: Coolant compositions, flavorant compositions and ingestible and topical compositions containing at least one coolant compound selected from monomenthyl succinate, alkali metal salts of monomenthyl succinate, alkaline earth metal salts of monomenthyl succinate and mixtures thereof. These compositions are found to provide a pleasant, long-lasting cooling effect without bitterness and the cooling effect manifests itself differently than the cooling effect of other known coolants. As a result, a complementary or synergistic effect can by obtained by combination with other coolants. Further, the succinate-based coolant compounds of the invention are found to enhance the sensation of alcohol in alcoholic beverages.Type: GrantFiled: August 29, 1995Date of Patent: March 10, 1998Assignee: V. MANE Fils S.A.Inventors: Jean M. Mane, Jean-Louis Ponge
-
Patent number: 5622992Abstract: The present invention relates to topical aromatic releasing compositions containing one or more volatile aromatic compounds selected from the group consisting of 3-1-menthoxy propane-1,2-diol, N-substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof. In further embodiments, these compositions are also useful for providing relief from nasal symptoms.Type: GrantFiled: March 7, 1996Date of Patent: April 22, 1997Assignee: The Procter & Gamble CompanyInventor: William F. Beck
-
Patent number: 5560913Abstract: The present invention relates to orally ingestible, pharmaceutical compositions containing at least one pharmaceutical active and a taste masking component.Type: GrantFiled: January 27, 1995Date of Patent: October 1, 1996Assignee: The Procter & Gamble CompanyInventor: Philip L. Kupper
-
Patent number: 5558879Abstract: A controlled release pharmaceutical tablet is disclosed which is based on:(a) a compressed core which contains:(i) a medicament;(ii) from 5 to 20% by weight of a water soluble osmotic agent based on the total weight of the compressed core;(iii) a water soluble pharmaceutically acceptable polymeric binder;(iv) a conventional pharmaceutical excipient; and(b) a dual layer membrane coating around said core which consists essentially of:(i) a first inner coating layer for sustained release of the medicament, said inner coating layer consisting essentially of a plasticized water insoluble pharmaceutically acceptable polymer and a pharmaceutically acceptable water soluble polymer, and;(ii) a second outer coating layer for immediate release of a medicament, said outer coating layer consisting essentially of an effective amount of a medicament and a water soluble polymer.The controlled release formulation is suitable for the once-a-day administration of medicaments.Type: GrantFiled: April 28, 1995Date of Patent: September 24, 1996Assignee: Andrx Pharmaceuticals, Inc.Inventors: Chih-Ming Chen, Der-Yang Lee
-
Patent number: 5534552Abstract: A clear, hypoallergenic sinus and allergy medication is orally administered in an aqueous, liquid dosage form. The formulation provides effective sinus and allergy relief without alcohol or dyes which adversely affect many allergy sufferers. Said relief is provided while still maintaining aesthetic appeal or pleasant taste and texture.Type: GrantFiled: March 2, 1994Date of Patent: July 9, 1996Assignee: Warner-Lambert CompanyInventor: Swati Bapat
-
Patent number: 5514665Abstract: Methods for reducing the risk of or preventing infections by bacterial pathogens in vivo. In particular, a method for reducing the risk of P. aeruginosa infection in vivo in compromised hosts such as cystic fibrosis patients. The methods involve the use of dextran or dextran sulphate as the active ingredient.Type: GrantFiled: October 3, 1994Date of Patent: May 7, 1996Assignee: University of British ColumbiaInventors: David P. Speert, Thomas C. Usher
-
Patent number: 5441938Abstract: A novel therapy for Pseudomonas aeruginosa infections, in particular in cystic fibrosis patients, is described. Macrophages provide the first line of defence in protecting the lung against bacterial infections. Nonetheless, Pseudomonas aeruginosa infections continue to be problematic in cystic fibrosis patients and are the leading cause of death in these patients. Previously, little was known regarding the factors which regulate the capacity of macrophages to mediate phagocytosis of Pseudomonas aeruginosa. The inventors have now shown that phagocytosis of nonopsonized Pseudomonas aeruginosa by macrophages is dependent upon the presence of glucose. They have also shown that the action of glucose is on the macrophage rather than the bacteria. Glucose therapy can therefore be used to prevent or combat Pseudomonas aeruginosa infections.Type: GrantFiled: May 26, 1992Date of Patent: August 15, 1995Assignee: University of British ColumbiaInventors: David Speert, Sameer Barghouthi, Siamon Gordon